Hyperliquid completes pre-market perpetual contract conversion for LINEA

Johnson & Johnson announced that its Tecvayli® combined with Darzalex Faspro® treatment regimen has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory multiple myeloma patients.

U.S. federal banking regulators clarify capital treatment rules for tokenized securities

Tevogen Bio Holdings (Tevogen) has recently taken a key step in its generic drug business strategy, signing a letter of intent to officially begin evaluating the potential acquisition of Apozeal Pharmaceuticals.

Tevogen Bio Holdings Inc is currently actively evaluating other transaction opportunities and has strategically focused its priorities on businesses related to the life sciences sector.